[1] PETRENKO A B，YAMAKURA T，BABA H，et al. The role of N-methyl-D-aspartate（NMDA）receptors in pain：a review. Anesth Analg，2003，97：1108-1116.

[2] AIYER R，MEHTA N，GUNGOR S，et al. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain，2018，34：450-467.

[3] MICHELET D，BRASHER C，HORLIN A L，et al. Ketamine for chronic non-cancer pain：a meta-analysis and trial sequential analysis of randomized controlled trials. Eur J Pain，2018，22：632-646.

[4] BREDLAU A L，THAKUR R，KORONES D N，et al. Ketamine for pain in adults and children with cancer：a systematic review and synthesis of the literature. Pain Med，2013，14：1505-1517.

[5] TRIMMEL H，HELBOK R，STAUDINGER T，et al. S（+）-ketamine：Current trends in emergency and intensive care medicine. Wien Klin Wochenschr，2018. doi：10.1007/s00508-017-1299-3.

[6] MIZIARA L E，SIMONI R F，ESTEVES L O，et al. Efficacy of continuous S（+）-ketamine infusion for postoperative pain control：a randomized placebo-controlled trial. Anesthesiol Res Pract，2016：6918327.

[7] WEINBROUM A A，RUDICK V，PARET G，et al. The role of dextromethorphan in pain control. Can J Anaesth，2000，47：585-596.

[8] SIU A，DRACHTMAN R. Dextromethorphan：a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev，2007，13：96-106.

[9] ILKJAER S，DIRKS J，BRENNUM J，et al. Effect of systemic N-methyl-D-aspartate receptor antagonist（dextromethorphan）on primary and secondary hyperalgesia in humans. Br J Anaesth，1997，79：600-605.

[10] DUEDAHL T H，DIRKS J，PETERSEN K B，et al. Intravenous dextromethorphan to human volunteers：relationship between pharmacokinetics and anti-hyperalgesic effect. Pain，2005，113：360-368.

[11] FUKUI S，KOMODA Y，NOSAKA S. Clinical application of amantadine，an NMDA antagonist，for neuropathic pain. J Anesth，2001，15：179-181.